G1 Therapeutics, Inc. Common Stock
GTHX
GTHX was delisted on the 17th of September, 2024.
94 hedge funds and large institutions have $741M invested in G1 Therapeutics, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 37 increasing their positions, 11 reducing their positions, and 4 closing their positions.
950% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 4
236% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 11
175% more capital invested
Capital invested by funds: $270M → $741M (+$471M)
65% more funds holding
Funds holding: 57 → 94 (+37)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$32.6M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$29.8M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$19.7M |
| 4 |
BlackRock
New York
|
+$14.3M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$12.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$6.08M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$4.74M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$3.2M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$508K |
| 5 |
EMG
Ellington Management Group
Old Greenwich,
Connecticut
|
-$294K |
GTHX Hedge Fund Activity: Q1 2018 in Review
94 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q1 2018, worth a combined $741M — up 175% from $270M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new GTHX positions and 4 closed out — a net gain of 38 holders — while 37 added to existing stakes and 11 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $32.6M. The largest seller was Franklin Resources, cutting an estimated $6.08M.
- 94 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q1 2018, up from 57 in Q4 2017.
- Funds reported $741M of G1 Therapeutics, Inc. Common Stock stock for Q1 2018, up 175% quarter-over-quarter.
- 42 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q1 2018 and 4 closed out, a net change of +38 holders.
- The largest G1 Therapeutics, Inc. Common Stock buyer in Q1 2018 was Wellington Management Group, an estimated $32.6M added.
- The largest G1 Therapeutics, Inc. Common Stock seller in Q1 2018 was Franklin Resources, an estimated $6.08M sold.
Based on aggregated 13F filings for Q1 2018.